
Given subcutaneously every 3 months, cemdisiran (Livsayis) is indicated for adults with AChR antibody–positive gMG and requires REMS enrollment.
Thomas Cohn, chief strategy officer at Armada Health Care, discusses the long term impact of the Affordable Care Act on specialty pharmacies.
Thomas Cohn, chief strategy officer at Armada Health Care, discusses the long term impact of the Affordable Care Act on specialty pharmacies.